Skip to main content
DOI:
10.1055/s-00034924
Nuklearmedizin - NuclearMedicine
Issue 03 ·
Volume 37 ·
1998
DOI: 10.1055/s-008-37986
Original Article
83
Sabri, O.;
Schulz, G.;
Zimny, M.;
Schreckenberger, M.;
Zimny, D.;
Wagenknecht, G.;
Kaiser, H. J.;
Dohmen, B. M.;
Bares, R.;
Büll, U.:
Determination of Factors Influencing the Outcome of Radioiodine Therapy in Patients with Graves’ Disease
90
Rink, Th.;
Holle, L.-H.;
Schroth, H.-J.;
Garth, H.:
Individual Monitoring of Thyrotropin Receptor Antibody Levels for Predicting the Course of Graves’ Disease
95
Hillenhinrichs, H.;
Emrich, D.:
Euthyroid Goitre with and without Functional Autonomy: A Comparison
101
Kleinenz, B.;
Förster, G.;
Wieler, H.;
Kahaly, G.;
Kaiser, K. P.;
Hansen, Ch.;
Willkomm, P.;
Ruhlmann, J.:
Study to the Combinatory Therapy of the Endemic Goitre by Two Thyroxin/Iodine Combinations
107
Melier, B.;
Lauer, I.;
Bähre, M.;
Richter, E.:
Einfluß der Radioiodtherapie auf die Uriniodausscheidung
113
Wellner, U.;
Eschner, W.;
Hillger, H. W.;
Schicha, H.:
The Exposure of Relatives to Patients of a Nuclear MedicaJ Ward after Radio Iodine Therapy by Inhalation of 131I in their Home
120
Laßmann, M.;
Hänscheid, H.;
Schelper, L.-F.;
Körber, C.;
Reiners, C.:
Measurement of Incorporation in Family Members of Patients with Benign Thyroid Diseases after Kadioiodiue Therapy
